Premature phase II study of amrubicin as palliative chemotherapy for previously treated malignant pleural mesothelioma

BACKGROUND: Treatment options for malignant pleural mesothelioma (MPM) are limited. Anthracyclines are considered key drugs for treating MPM. However, their use is limited by severe cardiac toxicities. Amrubicin (AMR) is a next‐generation anthracycline that is commonly used to treat lung cancer. Her...

Descripción completa

Detalles Bibliográficos
Autores principales: Watanabe, Kageaki, Okuma, Yusuke, Kawai, Shoko, Nagamata, Makoto, Hosomi, Yukio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons Australia, Ltd 2021
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8169308/
https://www.ncbi.nlm.nih.gov/pubmed/33830645
http://dx.doi.org/10.1111/1759-7714.13892

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8169308/
https://www.ncbi.nlm.nih.gov/pubmed/33830645
http://dx.doi.org/10.1111/1759-7714.13892

Ejemplares similares